Lipophilic statins inhibit YAP nuclear localization, co-activator activity and colony formation in pancreatic cancer cells and prevent the initial stages of pancreatic ductal adenocarcinoma in KrasG12D mice
Open accessThe DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
We examined the impact of statins on Yes-associated Protein (YAP) localization, phosphorylation and transcriptional activity in human and mouse pancreatic ductal adenocarcinoma (PDAC) cells. Exposure of sparse cultures of PANC-1 and MiaPaCa-2 cells to cerivastatin or simvastatin induced a striking re-localization of YAP from the nucleus to the cytoplasm and inhibited the expression of the YAP/TEAD-regulated genes Connective Tissue Growth Factor (CTGF) and Cysteine-rich angiogenic inducer 61 (CYR61). Statins also prevented YAP nuclear import and expression of CTGF and CYR61 stimulated by the mitogenic combination of insulin and neurotensin in dense culture of these PDAC cells. Cerivastatin, simvastatin, atorvastatin and fluvastatin also inhibited colony formation by PANC-1 and MiaPaCa-2 cells in a dose-dependent manner. In contrast, the hydrophilic statin pravastatin did not exert any inhibitory effect even at a high concentration (10 μM). Mechanistically, cerivastatin did not alter the phosphorylation of YAP at Ser127 in either PANC-1 or MiaPaCa-2 cells incubated without or with neurotensin and insulin but blunted the assembly of actin stress fiber in these cells. We extended these findings with human PDAC cells using primary KC and KPC cells, (expressing KrasG12D or both KrasG12D and mutant p53, respectively) isolated from KC or KPC mice. Using cultures of these murine cells, we show that lipophilic statins induced striking YAP translocation from the nucleus to the cytoplasm, inhibited the expression of Ctgf, Cyr61 and Birc5 and profoundly inhibited colony formation of these cells. Administration of simvastatin to KC mice subjected to diet-induced obesity prevented early pancreatic acini depletion and PanIN formation. Collectively, our results show that lipophilic statins restrain YAP activity and proliferation in pancreatic cancer cell models in vitro and attenuates early lesions leading to PDAC in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Statins, including simvastatin, have also shown antifibrotic potential in preclinical studies by promoting YAP cytoplasmic retention and inactivation, offering opportunities for drug repurposing (144, 145).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [144]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · cited 2×
“It has been anticipated that PDAC will be the 3 leading cause of cancer-related mortalities in the USA by the end of 2018 [1] and projected to become the 2 leading cause of cancer-related mortality in the USA before 2030 [2].”
BackgroundEtienne-Manneville, S., & Hall, A. (2002) · Nature · doi:10.1038/nature01148 · Cited by 4,201 · cited 1×
“Rho plays a critical role in F-actin organization and in the assembly of actin stress fibers in a variety of cell types [70].”
BackgroundCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · cited 1×
“Virtually all PanIN lesions and invasive PDAC entail activating mutations in the KRAS oncogene, which represent an initiating event in the development of the disease [5, 6].”
BackgroundA pathology atlas of the human cancer transcriptome
Uhlen, M., Zhang, C., Lee, S., Sjöstedt, E., Fagerberg, L., Bidkhori, G., Benfeitas, R., Arif, M., Liu, Z., Edfors, F., et al. (2017) · Science · doi:10.1126/science.aan2507 · Cited by 3,371 · cited 1×
“We used the Pathology Atlas [62] based on the integration of publicly available data from The Cancer Genome Atlas (TCGA) and data generated within the framework of the Human Protein Atlas (HPA) and analyzed transcriptomics and survival in 176 PDAC patients [62].”
MethodPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“PDAC arises from precursor lesions, the most common of which are pancreatic intraepithelial neoplasia (PanIN) [3, 4].”
BackgroundPancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · cited 1×
“Virtually all PanIN lesions and invasive PDAC entail activating mutations in the KRAS oncogene, which represent an initiating event in the development of the disease [5, 6].”
BackgroundSelf-citationYAP/TAZ at the Roots of Cancer
Zanconato, F., Cordenonsi, M., & Piccolo, S. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.005 · Cited by 1,970 · cited 1×
“The highly conserved transcriptional co-activator YAP and its paralog TAZ, originally identified in Drosophila, are emerging as potent oncogenes for a variety of cell types [20, 64].”
BackgroundMechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 3×
“The transfer of the geranylgeranyl moiety of GG-PP to a COOH-terminal cysteine of Rho GTPases is critical for their membrane localization and function in signal transduction through actin remodeling [12].”
BackgroundGenetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Force triggers YAP nuclear entry by regulating transport across nuclear pores
Elosegui-Artola, A., Andreu, I., Beedle, A. E. M., Lezamiz, A., Uroz, M., Kosmalska, A. J., Oria, R., Kechagia, J. Z., Rico-Lastres, P., Le Roux, A.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.008 · Cited by 1,491 · cited 1×
“Interestingly, Rho-induced actomyosin-based tension causes YAP/TAZ activation, as well as proposed to “open” nuclear pores for YAP/TAZ nuclear import [71, 72].”
BackgroundMechanobiology of YAP and TAZ in physiology and disease
Panciera, T., Azzolin, L., Cordenonsi, M., & Piccolo, S. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.87 · Cited by 1,461 · cited 1×
“A considerable body of evidence indicates that multiple signaling inputs regulate the activity of YAP through the organization of filamentous (F) actin [68, 69].”
BackgroundThe Hippo pathway: regulators and regulations.
Yu, F.-X., & Guan, K.-L. (2013) · Genes & Development · doi:10.1101/gad.210773.112 · Cited by 1,231
The emerging roles of YAP and TAZ in cancer
Moroishi, T., Hansen, C. G., & Guan, K.-L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3876 · Cited by 1,145 · cited 1×
“The highly conserved transcriptional co-activator YAP and its paralog TAZ, originally identified in Drosophila, are emerging as potent oncogenes for a variety of cell types [20, 64].”
BackgroundYAP/TAZ upstream signals and downstream responses
Totaro, A., Panciera, T., & Piccolo, S. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0142-z · Cited by 1,086 · cited 3×
“The organization of the actin cytoskeleton plays a central role in the regulation of YAP localization and transcriptional activity independently of YAP phosphorylation [13].”
BackgroundInfluentialMutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Metabolic control of YAP and TAZ by the mevalonate pathway
Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2936 · Cited by 776 · cited 2×
“Previous studies resulted in differing conclusions concerning the role of the Hippo pathway and YAP phosphorylation in the mechanism by which statins promote YAP localization to the cytoplasm [35, 37] but none of these studies were performed in PDAC cells.”
BackgroundResultYap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
The Role of Cholesterol in Cancer
Kuzu, O. F., Noory, M. A., & Robertson, G. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2613 · Cited by 708
Benham-Pyle, B. W., Pruitt, B. L., & Nelson, W. J. (2015) · Science · doi:10.1126/science.aaa4559 · Cited by 534
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer
Gazzerro, P., Proto, M. C., Gangemi, G., Malfitano, A. M., Ciaglia, E., Pisanti, S., Santoro, A., Laezza, C., & Bifulco, M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004994 · Cited by 457 · cited 2×
“Statins are specific inhibitors of the 3-hydroxy-methylglutaryl (HMG) CoA reductase [32, 33], the ratelimiting enzyme in the generation of mevalonate, the first step in the biosynthesis of isoprenoids, leading to farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GG-PP) and cholesterol [34].”
BackgroundDysregulation of the mevalonate pathway promotes transformation
Clendening, J. W., Pandyra, A., Boutros, P. C., Ghamrasni, S. E., Khosravi, F., Trentin, G. A., Martirosyan, A., Hakem, A., Hakem, R., Jurisica, I., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910258107 · Cited by 417
Zhang, W., Nandakumar, N., Shi, Y., Manzano, M., Smith, A., Graham, G., Gupta, S., Vietsch, E. E., Laughlin, S. Z., Wadhwa, M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2005049 · Cited by 360 · cited 2×
“Recent studies demonstrated that the YAP/TAZ pathway plays a critical role in promoting the initial stages of PDAC development, namely depletion of intact acini (acinar-ductal metaplasia) and formation of PanIN lesions [14, 15].”
BackgroundWang, Z., Wu, Y., Wang, H., Zhang, Y., Mei, L., Fang, X., Zhang, X., Zhang, F., Chen, H., Liu, Y., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319190110 · Cited by 316 · cited 3×
“Previous studies resulted in differing conclusions concerning the role of the Hippo pathway and YAP phosphorylation in the mechanism by which statins promote YAP localization to the cytoplasm [35, 37] but none of these studies were performed in PDAC cells.”
BackgroundResultKisfalvi, K., Eibl, G., Sinnett-Smith, J., & Rozengurt, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0418 · Cited by 315
Self-citationPrecursors to Invasive Pancreatic Cancer
Maitra, A., Fukushima, N., Takaori, K., & Hruban, R. H. (2005) · Advances in Anatomic Pathology · doi:10.1097/01.pap.0000155055.14238.25 · Cited by 291 · cited 1×
“PDAC arises from precursor lesions, the most common of which are pancreatic intraepithelial neoplasia (PanIN) [3, 4].”
BackgroundPlouffe, S. W., Lin, K. C., Moore, J. L., Tan, F. E., Ma, S., Ye, Z., Qiu, Y., Ren, B., & Guan, K.-L. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.002715 · Cited by 252
Rozengurt, E., Sinnett-Smith, J., & Kisfalvi, K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2229 · Cited by 247
Self-citationDas, A., Fischer, R. S., Pan, D., & Waterman, C. M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.708313 · Cited by 243
Targeting tumor cell metabolism with statins
Clendening, J. W., & Penn, L. Z. (2012) · Oncogene · doi:10.1038/onc.2012.6 · Cited by 239 · cited 1×
“Statins are specific inhibitors of the 3-hydroxy-methylglutaryl (HMG) CoA reductase [32, 33], the ratelimiting enzyme in the generation of mevalonate, the first step in the biosynthesis of isoprenoids, leading to farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GG-PP) and cholesterol [34].”
BackgroundDNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Parrales, A., Ranjan, A., Iyer, S. V., Padhye, S., Weir, S. J., Roy, A., & Iwakuma, T. (2016) · Nature Cell Biology · doi:10.1038/ncb3427 · Cited by 239
Protein kinases of the Hippo pathway: Regulation and substrates
Avruch, J., Zhou, D., Fitamant, J., Bardeesy, N., Mou, F., & Barrufet, L. R. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.07.002 · Cited by 228 · cited 1×
“The Hippo pathway consists of a serine/threonine kinase cascade in which Mst1/2 kinases phosphorylate and activate Lats1/2, which phosphorylate YAP and TAZ at specific residues that regulate their localization and protein stability [11, 12].”
BackgroundGruber, R., Panayiotou, R., Nye, E., Spencer-Dene, B., Stamp, G., & Behrens, A. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.006 · Cited by 218 · cited 2×
“Recent studies demonstrated that the YAP/TAZ pathway plays a critical role in promoting the initial stages of PDAC development, namely depletion of intact acini (acinar-ductal metaplasia) and formation of PanIN lesions [14, 15].”
BackgroundYes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma
Murakami, S., Shahbazian, D., Surana, R., Zhang, W., Chen, H., Graham, G. T., White, S. M., Weiner, L. M., & Yi, C. (2017) · Oncogene · doi:10.1038/onc.2016.288 · Cited by 215 · cited 1×
“Several studies indicate that YAP/TAZ is up-regulated in PDAC tumor samples [24–26] and higher expression of YAP is correlated with poorer survival in PDAC patients [17, 27].”
BackgroundControl of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways
Santinon, G., Pocaterra, A., & Dupont, S. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.11.004 · Cited by 165
Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP
Straßburger, K., Tiebe, M., Pinna, F., Breuhahn, K., & Teleman, A. A. (2012) · Developmental Biology · doi:10.1016/j.ydbio.2012.05.008 · Cited by 164
Dawson, D. W., Hertzer, K., Moro, A., Donald, G., Chang, H.-H., Go, V. L., Pandol, S. J., Lugea, A., Gukovskaya, A. S., Li, G., et al. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0065 · Cited by 153 · cited 4×
“Treatment with simvastatin significantly attenuated the loss of intact acini (histological images in Fig 7A and 7B; quantification in Fig 7C), markedly reduced the pancreatitis score (calculated as in [8, 9]) and the formation of PanIN-3 lesions (quantification in Fig 7E) induced by DIO.”
BackgroundResultInfluentialSelf-citationMechanoregulation and pathology of YAP/TAZ via Hippo and non‐Hippo mechanisms
Dobrokhotov, O., Samsonov, M., Sokabe, M., & Hirata, H. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0202-9 · Cited by 150 · cited 1×
“Interestingly, Rho-induced actomyosin-based tension causes YAP/TAZ activation, as well as proposed to “open” nuclear pores for YAP/TAZ nuclear import [71, 72].”
BackgroundMei, Z., Liang, M., Li, L., Zhang, Y., Wang, Q., & Yang, W. (2017) · International Journal of Cancer · doi:10.1002/ijc.30526 · Cited by 146 · cited 2×
“In line with this conclusion, recent epidemiological studies imply that the use of statins is associated with beneficial effects in PDAC [38–47], and other malignancies [48].”
BackgroundResultChang, H.-H., Moro, A., Takakura, K., Su, H.-Y., Mo, A., Nakanishi, M., Waldron, R. T., French, S. W., Dawson, D. W., Hines, O. J., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0184455 · Cited by 143
Self-citationRozengurt, E., Sinnett-Smith, J., & Eibl, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0005-2 · Cited by 137 · cited 2×
“In this context, a number of studies indicate that YAP and TAZ are overactive in PDAC patient tumor samples [24, 65, 66] and associated with poor survival [17].”
BackgroundSelf-citationLipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling
Beckwitt, C. H., Shiraha, K., & Wells, A. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197422 · Cited by 129 · cited 1×
“Because statins inhibited PI3K activity in other cell types [60], and this enzyme contributes to YAP activation in PDAC cells [58], we determined the effect of cerivastatin on the activity of PI3K in intact PANC-1 cells.”
BackgroundThe YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis
Kovar, H., Bierbaumer, L., & Radic-Sarikas, B. (2020) · Cells · doi:10.3390/cells9040972 · Cited by 127
Funahashi, H., Satake, M., Dawson, D., Huynh, N.-A., Reber, H. A., Hines, O. J., & Eibl, G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0970 · Cited by 116
Self-citationYang, S., Zhang, L., Purohit, V., Shukla, S. K., Chen, X., Yu, F., Fu, K., Chen, Y., Solheim, J., Singh, P. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5935 · Cited by 106
Soares, H. P., Ming, M., Mellon, M., Young, S. H., Han, L., Sinnet-Smith, J., & Rozengurt, E. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0669 · Cited by 97
Self-citationMorvaridi, S., Dhall, D., Greene, M. I., Pandol, S. J., & Wang, Q. (2015) · Scientific Reports · doi:10.1038/srep16759 · Cited by 96
KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops
Eibl, G., & Rozengurt, E. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.007 · Cited by 85 · cited 1×
“Consequently, we determined the effect of statin on pancreatic pre-neoplastic lesions in KC mice subjected to diet-induced obesity that accelerates the appearance and stage of these lesions [16].”
BackgroundSelf-citationStatin use and risk of pancreatic cancer: Results from a large, clinic‐based case‐control study
Walker, E. J., Ko, A. H., Holly, E. A., & Bracci, P. M. (2015) · Cancer · doi:10.1002/cncr.29256 · Cited by 79
Mevalonate Metabolism in Immuno-Oncology
Gruenbacher, G., & Thurnher, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01714 · Cited by 78 · cited 1×
“Statins are specific inhibitors of the 3-hydroxy-methylglutaryl (HMG) CoA reductase [32, 33], the ratelimiting enzyme in the generation of mevalonate, the first step in the biosynthesis of isoprenoids, leading to farnesyl pyrophosphate (FPP), geranylgeranyl pyrophosphate (GG-PP) and cholesterol [34].”
BackgroundInfluence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer
Huang, B. Z., Chang, J. I., Li, E., Xiang, A. H., & Wu, B. U. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw275 · Cited by 75
Mohammed, A., Qian, L., Janakiram, N. B., Lightfoot, S., Steele, V. E., & Rao, C. V. (2012) · International Journal of Cancer · doi:10.1002/ijc.27456 · Cited by 74
Screening for YAP inhibitors identifies statins as modulators of fibrosis
Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0296oc · Cited by 72
Rozengurt, E. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00357 · Cited by 71
Self-citationJeon, C. Y., Pandol, S. J., Wu, B., Cook-Wiens, G., Gottlieb, R. A., Merz, N. B., & Goodman, M. T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121783 · Cited by 69
Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells
Hao, F., Xu, Q., Zhao, Y., Stevens, J. V., Young, S. H., Sinnett-Smith, J., & Rozengurt, E. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0023 · Cited by 68
Self-citationJian-Yu, E., Graber, J. M., Lu, S.-E., Lin, Y., Lu-Yao, G., & Tan, X.-L. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170412145232 · Cited by 67
Xie, D., Cui, J., Xia, T., Jia, Z., Wang, L., Wei, W.-F., Zhu, A., Gao, Y., Xie, K., & Quan, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5772 · Cited by 62 · cited 1×
“In this context, a number of studies indicate that YAP and TAZ are overactive in PDAC patient tumor samples [24, 65, 66] and associated with poor survival [17].”
BackgroundChen, M., Tsan, Y., Liou, J., Lee, Y., Wu, M., Chiu, H., Wang, H., & Chen, P. (2016) · International Journal of Cancer · doi:10.1002/ijc.29813 · Cited by 59
Kisfalvi, K., Guha, S., & Rozengurt, E. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20187 · Cited by 59
Self-citationStatin Use and Its Impact on Survival in Pancreatic Cancer Patients
Lee, H. S., Lee, S. H., Lee, H. J., Chung, M. J., Park, J. Y., Park, S. W., Song, S. Y., & Bang, S. (2016) · Medicine · doi:10.1097/md.0000000000003607 · Cited by 58
Impact of Statin Use on Survival in Patients Undergoing Resection for Early-Stage Pancreatic Cancer
Wu, B. U., Chang, J., Jeon, C. Y., Pandol, S. J., Huang, B., Ngor, E. W., Difronzo, A. L., & Cooper, R. M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.217 · Cited by 57
Cancer Prevention and Interception: A New Era for Chemopreventive Approaches
Albini, A., DeCensi, A., Cavalli, F., & Costa, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0695 · Cited by 56
Cilia loss sensitizes cells to transformation by activating the mevalonate pathway
Deng, Y.-Z., Cai, Z., Shi, S., Jiang, H., Shang, Y.-R., Ma, N., Wang, J.-J., Guan, D.-X., Chen, T.-W., Rong, Y.-F., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20170399 · Cited by 55
Self-citationKisfalvi, K., Rey, O., Young, S. H., Sinnett-Smith, J., & Rozengurt, E. (2007) · Endocrinology · doi:10.1210/en.2006-1711 · Cited by 54
Self-citationChang, H.-H., & Eibl, G. (2019) · Cells · doi:10.3390/cells8070673 · Cited by 51
Self-citationVariability in statin-induced changes in gene expression profiles of pancreatic cancer
Gbelcová, H., Rimpelová, S., Ruml, T., Fenclová, M., Kosek, V., Hajšlová, J., Strnad, H., Kolář, M., & Vítek, L. (2017) · Scientific Reports · doi:10.1038/srep44219 · Cited by 48 · cited 1×
“This is likely due to the low uptake of pravastatin in pancreatic cancer cells [59].”
BackgroundArchibugi, L., Piciucchi, M., Stigliano, S., Valente, R., Zerboni, G., Barucca, V., Milella, M., Maisonneuve, P., Delle Fave, G., & Capurso, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-13430-z · Cited by 48
Carey, F. J., Little, M. W., Pugh, T., Ndokera, R., Ing, H., Clark, A., Dennison, A. R., Metcalfe, M. S., Robinson, R. J., & Hart, A. R. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-013-2778-7 · Cited by 45
Wang, J., Sinnett‐Smith, J. W., Stevens, J. V., Young, S. H., & Rozengurt, E. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.711275 · Cited by 45
Self-citationStatin use and pancreatic cancer risk in two prospective cohort studies
Hamada, T., Khalaf, N., Yuan, C., Babic, A., Morales-Oyarvide, V., Qian, Z. R., Nowak, J. A., Ng, K., Kraft, P., Rubinson, D. A., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1430-x · Cited by 43 · cited 1×
“Although a recent study failed to detect an effect of statins in lowering PDAC risk [73], a follow up study of the same data reported an increased survival in PDAC patients with regular pre-diagnosis use of statins [74].”
ResultPancreas lineage allocation and specification are regulated by sphingosine-1-phosphate signalling
Serafimidis, I., Rodríguez-Aznar, E., Lesche, M., Yoshioka, K., Takuwa, Y., Dahl, A., Pan, D., & Gavalas, A. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2000949 · Cited by 34 · cited 1×
“Recent evidence indicates that the transcriptional co-activators Yes-Associated Protein (YAP) and WW-domain-containing Transcriptional co-Activator with PDZ-binding motif (TAZ), two central effectors of the highly conserved Hippo pathway [11–13], act as potent oncogenes in PDAC [14–17] and in the control of differenti…”
BackgroundWu, Z., Wang, C., Chen, Y., Sun, Z., & Yan, W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s225602 · Cited by 26
Hamada, T., Khalaf, N., Yuan, C., Morales-Oyarvide, V., Babic, A., Nowak, J. A., Qian, Z. R., Ng, K., Rubinson, D. A., Kraft, P., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.02.022 · Cited by 25
Young, S. H., & Rozengurt, E. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.036 · Cited by 22
Self-citationModels and Mechanisms of High-Fat Diet (HFD) Promotion of Pancreatic Cancer
Chang, H.-H., Eibl, G., & Rozengurt, E. (2015) · Energy balance and cancer · doi:10.1007/978-3-319-16733-6_10 · Cited by 2
Self-citation
Research works printed but not linked: 2
- Yang S, Zhang L, Purohit V, Shukla SK, Chen X, Yu F, et al Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3 2015 10.18632/oncotarget.5935 26440309 PMC4742158 · DOI · Paper page
- Hamada T, Khalaf N, Yuan C, Morales-Oyarvide V, Babic A, Nowak JA, et al Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol. 2018; 16(8): 1300– 6.e3. 10.1016/j.cgh.2018.02.022 29474971 PMC6056316 · DOI · Paper page
Cited by
Insights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
Vell, M. S., Loomba, R. S., Krishnan, A., Wangensteen, K. J., Trebicka, J., Creasy, K. T., Trautwein, C., Scorletti, E., Seeling, K. S., Hehl, L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.20222 · Cited by 137
The YAP/TAZ Pathway in Osteogenesis and Bone Sarcoma Pathogenesis
Kovar, H., Bierbaumer, L., & Radic-Sarikas, B. (2020) · Cells · doi:10.3390/cells9040972 · Cited by 127
Mokhtari, R. B., Ashayeri, N., Baghaie, L., Sambi, M., Satari, K., Baluch, N., Bosykh, D. A., Szewczuk, M. R., & Chakraborty, S. (2023) · Cancers · doi:10.3390/cancers15133468 · Cited by 100
Ortega, Á., Vera, I., Díaz, M. I., Navarro, C., Rojas, M., Torres, W., Parra, H., Salazar, J. J., Sanctis, J. B. D., & Bermúdez, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010430 · Cited by 94
Metadata
- Authors
- Hao, F., Xu, Q., Wang, J., Yu, S., Chang, H.-H., Sinnett-Smith, J., Eibl, G., & Rozengurt, E.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Rozengurt, Enrique
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-05-17
- Volume
- 14
- Issue
- 5
- Pages
- e0216603
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6524808
- OpenAlex
- W2945457209
- Cited by
- 55
- References
- 77
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 11 · 2023: 10 · 2022: 9 · 2021: 6 · 2020: 9 · 2019: 2
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, public-domain)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK100405, P30DK041301)
- National Cancer Institute (P01CA163200)
- U.S. Department of Veterans Affairs (I01BX003801)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- lipophilic statins, YAP, pancreatic ductal adenocarcinoma, cerivastatin, simvastatin, YAP nuclear localization, YAP phosphorylation, connective tissue growth factor, CYR61, survivin, colony formation, stress fibers, KRAS G12D, KPC mice, pancreatic intraepithelial neoplasia, diet-induced obesity
- MeSH terms
- YAP-Signaling Proteins, Animals, Cell Nucleus, Colony-Forming Units Assay, Humans, Mutation, Pancreatic Neoplasms, Phosphorylation, Transcription Factors, Tumor Cells, Cultured, Gene Expression Regulation, Neoplastic, Proto-Oncogene Proteins p21(ras), Hydroxymethylglutaryl-CoA Reductase Inhibitors, Protein Transport, Carcinoma, Pancreatic Ductal, Adaptor Proteins, Signal Transducing, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.